201 related articles for article (PubMed ID: 18055869)
1. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia.
Dearden C; Wade R; Else M; Richards S; Milligan D; Hamblin T; Catovsky D; ; ;
Blood; 2008 Feb; 111(4):1820-6. PubMed ID: 18055869
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.
Mauro FR; Foa R; Cerretti R; Giannarelli D; Coluzzi S; Mandelli F; Girelli G
Blood; 2000 May; 95(9):2786-92. PubMed ID: 10779422
[TBL] [Abstract][Full Text] [Related]
3. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
Catovsky D; Richards S; Matutes E; Oscier D; Dyer M; Bezares RF; Pettitt AR; Hamblin T; Milligan DW; Child JA; Hamilton MS; Dearden CE; Smith AG; Bosanquet AG; Davis Z; Brito-Babapulle V; Else M; Wade R; Hillmen P; ;
Lancet; 2007 Jul; 370(9583):230-239. PubMed ID: 17658394
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine.
Di Raimondo F; Giustolisi R; Cacciola E; O'Brien S; Kantarjian H; Robertson LB; Keating MJ
Leuk Lymphoma; 1993 Sep; 11(1-2):63-8. PubMed ID: 8220155
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
6. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Skowronska A; Parker A; Ahmed G; Oldreive C; Davis Z; Richards S; Dyer M; Matutes E; Gonzalez D; Taylor AM; Moss P; Thomas P; Oscier D; Stankovic T
J Clin Oncol; 2012 Dec; 30(36):4524-32. PubMed ID: 23091097
[TBL] [Abstract][Full Text] [Related]
7. The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.
Else M; Wade R; Oscier D; Catovsky D
Br J Haematol; 2016 Jan; 172(2):228-37. PubMed ID: 26457986
[TBL] [Abstract][Full Text] [Related]
8. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Martell RE; Larson RA; Schiffer CA
J Clin Oncol; 2001 Aug; 19(16):3611-21. PubMed ID: 11504743
[TBL] [Abstract][Full Text] [Related]
9. Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Mulligan SP; Karlsson K; Strömberg M; Jønsson V; Gill D; Hammerström J; Hertzberg M; McLennan R; Uggla B; Norman J; Wallvik J; Sundström G; Johansson H; Brandberg Y; Liliemark J; Juliusson G;
Leuk Lymphoma; 2014 Dec; 55(12):2769-77. PubMed ID: 24524339
[TBL] [Abstract][Full Text] [Related]
10. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
11. CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.
Johnson GG; Lin K; Cox TF; Oates M; Sibson DR; Eccles R; Lloyd B; Gardiner LJ; Carr DF; Pirmohamed M; Strefford JC; Oscier DG; Gonzalez de Castro D; Else M; Catovsky D; Pettitt AR
Blood; 2013 Dec; 122(26):4253-8. PubMed ID: 24128861
[TBL] [Abstract][Full Text] [Related]
12. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
Dearden CE; Richards S; Else M; Catovsky D; Hillmen P
Cancer; 2011 Jun; 117(11):2452-60. PubMed ID: 24048793
[TBL] [Abstract][Full Text] [Related]
15. Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia.
Tertian G; Cartron J; Bayle C; Rudent A; Lambert T; Tchernia G
Hematol Cell Ther; 1996 Aug; 38(4):359-60. PubMed ID: 8891729
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine in chronic lymphocytic leukaemia.
Elter T; Hallek M; Engert A
Expert Opin Pharmacother; 2006 Aug; 7(12):1641-51. PubMed ID: 16872267
[TBL] [Abstract][Full Text] [Related]
17. Disease-specific complications of chronic lymphocytic leukemia.
Dearden C
Hematology Am Soc Hematol Educ Program; 2008; ():450-6. PubMed ID: 19074125
[TBL] [Abstract][Full Text] [Related]
18. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
Gonzalez D; Martinez P; Wade R; Hockley S; Oscier D; Matutes E; Dearden CE; Richards SM; Catovsky D; Morgan GJ
J Clin Oncol; 2011 Jun; 29(16):2223-9. PubMed ID: 21483000
[TBL] [Abstract][Full Text] [Related]
19. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
Weiss MA; Glenn M; Maslak P; Rahman Z; Noy A; Zelenetz A; Scheinberg DA; Golde DW
Leukemia; 2000 Sep; 14(9):1577-82. PubMed ID: 10995003
[TBL] [Abstract][Full Text] [Related]
20. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
Borthakur G; O'Brien S; Wierda WG; Thomas DA; Cortes JE; Giles FJ; Kantarjian HM; Lerner S; Keating MJ
Br J Haematol; 2007 Mar; 136(6):800-5. PubMed ID: 17341265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
